Health outcomes in multiple sclerosis

Current Opinion in Neurology

Volumn 17, Issue 3, 2004, Pages 257-261

  Flachenecker, Peter ^a   Rieckmann, Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cost effectiveness; Costs and cost analysis; Health outcome; Multiple sclerosis; Quality of life

Indexed keywords

BACLOFEN; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; RALENOVA; RECOMBINANT BETA INTERFERON; TIZANIDINE;

ABSENTEEISM; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DISEASE SEVERITY; ECONOMIC ASPECT; HUMAN; MEDICAL RESEARCH; METHODOLOGY; MULTIPLE SCLEROSIS; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; RETIREMENT; REVIEW; SPASTICITY;

BIOLOGICAL RESPONSE MODIFIERS; COST-BENEFIT ANALYSIS; HUMANS; INTERFERON-BETA; MITOXANTRONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDES; QUALITY OF LIFE;

EID: 2642517103     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200406000-00004     Document Type: Review

References (25)

1. Henriksson F, Jönsson B. The economic evaluation and consequences of multiple sclerosis. Int MS J 2000; 7:9-17.
2. Forbes RB, Lees A, Waugh N, Swingler RJ. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ 1999; 319:1529-1533.
3. Ellis SJ. Cost utility of drugs for multiple sclerosis. Analysis goes too far. BMJ 2000; 320:1475-1476.
4. Flachenecker P, Rieckmann P. Early intervention in multiple sclerosis: better outcomes for patients and society? Drugs 2003; 63:1525-1533. This paper reviews COI and cost-effectiveness studies in MS and puts them into the context of early immunomodulatory therapies.
5. Bryant J, Clegg A, Milne R. Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast. BMJ 2000; 320:1474-1475.
6. Clegg A, Bryant J. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. Expert Opin Pharmacother 2001; 2:623-639.
7. Miltenburger C, Kobelt G. Quality of life and cost of multiple sclerosis. Clin Neurol Neurosurg 2002; 104:272-275.
8. Henriksson F, Fredrikson S, Masterman T, Jonsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001; 8:27-35.
9. Kobelt G, Lindgren P, Smala A, et al., and the German Cost of MS Study Group. Cost and quality of life in multiple sclerosis. An observational study in Germany. Health Econ Prevent Care 2001; 2:60-68.
10. Kobelt G, Lindgren P, Parkin D, et al. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the United Kingdom. EFI Research Report 398. Stockholm: Stockholm School of Economics; 2000.
11. Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002; 249:152-163.
12. Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000; 6:91-98.
13. O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003; 3:17.
14. Kobelt G, Jonsson L, Henriksson F, et al. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care 2000; 16:768-780.
15. Kobelt G, Jonsson L, Miltenburger C, Jonsson B. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis using natural history disease data. Int J Technol Assess Health Care 2002; 18:127-138.
16. Kendrick M, Johnson KI. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective. Pharmacoeconomics 2000; 18:45-53.
17. Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health 2002; 5:44-54.
18. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003; 326:522-525. One of the most recent cost-effectiveness study in MS comparing IFNβ-1a (Rebif 22 μg, Rebif 44 μg and Avonex), IFNβ-1b (Betaferon) and glatiramer acetate in RR-MS and SP-MS, with the mean cost per QALY being highest in glatiramer acetate.
19. Rubio-Terres C, Aristegui Ruiz I, Medina Redorido F, Izquierdo Ayuso G. Cost-utility analysis of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain. Farm Hosp 2003; 27:159-165.
20. Hartung HP, Gonsette R, König N, et al., and the Mitoxantrone in Multiple Sclerosis Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360:2018-2025.
21. Touchette DR, Durgin TL, Wanke LA, Goodkin DE. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin Ther 2003; 25:611-634. The first cost-effectiveness study of mitoxantrone in MS demonstrating a favourable effect of mitoxantrone compared with IFN-β-1b. However, the cost-utility-ratio for IFN-β was $US338 738 from the insurer's, and $US245 700 from the societal perspective, values that were nearly ten times higher than those obtained in earlier studies [14, 15] using the same clinical data from the European IFN-β-study in SP-MS. The most dramatic difference, as discussed by the authors, are the discrepancies in costs and utility used underlining the importance of the methodology of health outcome studies in the economic evaluation of multiple sclerosis.
22. Rushton DN, Lloyd AC, Anderson PM. Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity. Pharmacoeconomics 2002; 20:827-837.
23. Pozzilli C, Brunetti M, Amicosante AM, et al. Home based management in multiple sclerosis: results of a randomised controlled trial. J Neurol Neurosurg Psychiatry 2002; 73:250-255.
24. Porter B, Keenan E, Record E, Thompson AJ. Diagnosis of MS: a comparison of three different clinical settings. Mult Scler 2003; 9:431-439.
25. Detournay B. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis. Value Health 2002; 5:1-2.